<i>FGFR</i> Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy

Introduction: Diagnostic classification of thyroid malignancy is primarily accomplished through examination of histomorphological features and may be substantiated and clarified by molecular data.1–3 Individual molecular drivers show relatively robust and specific associations with histological subtypes of thyroid malignancy, including BRAF sequence variants and kinase gene fusions in papillary thyroid carcinoma, predominantly RAS variants in follicular-patterned neoplasia,4 and additional “late” mutations affecting TERT promoter, TP53, and the PI3K/AKT/PTEN pathway in high-grade malignancies.5,6 Given the oncogenic role of FGFR, particularly FGFR1-3,7,8 the goal of this study was to explore the role of FGFR in thyroid carcinoma biology.

Authors

Institutions

Publication Details

Journal
VideoEndocrinology
Published
2024-09-01
DOI
https://doi.org/10.1089/ve.2024.0016
Primary Topic
Fibroblast Growth Factor Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy

Bayan Alzumaili, Mark F Sabbagh, A. John Iafrate, Lori J. Wirth et al.
VideoEndocrinology
Fibroblast Growth Factor Research
article

FGFR Alterations in Thyroid Carcinoma: A Novel Class of Primary Drivers with Significant Therapeutic Implications and Secondary Molecular Events Potentially Mediating Resistance in Thyroid Malignancy

Bayan Alzumaili, Mark F Sabbagh, A. John Iafrate, Lori J. Wirth, Vânia Nosé, Brennan Decker, Tyler Janovitz, Peter M. Sadow, Adam S. Fisch, Stephanie Siegmund, William C. Faquin, Jochen K. Lennerz, Justine A. Barletta, Valentina Nardi, Long P. Le, Dora Dias-Santagata, Gregory W. Randolph
article en

Abstract

Introduction: Diagnostic classification of thyroid malignancy is primarily accomplished through examination of histomorphological features and may be substantiated and clarified by molecular data.1–3 Individual molecular drivers show relatively robust and specific associations with histological subtypes of thyroid malignancy, including BRAF sequence variants and kinase gene fusions in papillary thyroid carcinoma, predominantly RAS variants in follicular-patterned neoplasia,4 and additional “late” mutations affecting TERT promoter, TP53, and the PI3K/AKT/PTEN pathway in high-grade malignancies.5,6 Given the oncogenic role of FGFR, particularly FGFR1-3,7,8 the goal of this study was to explore the role of FGFR in thyroid carcinoma biology.

VideoEndocrinologyVol. 11(3)
Brigham and Women's Hospital (US), Massachusetts Eye and Ear Infirmary (US), Harvard University (US), Massachusetts General Hospital (US), Foundation Medicine (United States)
Good health and well-being
Openalex Percentile: Top 87%
Fibroblast Growth Factor Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.